Maximize the value of innovation

Idorsia considers sophisticated partnerships to strategically access technologies or products, and to maximize the value of our discovery engine and clinical pipeline. In general, the purposes of our partnerships are to:

  • Complement internal innovation with external projects
  • Find suitable partners for maximizing the value of internal projects

Collaboration Agreement with Janssen Biotech

Idorsia and Janssen Biotech have entered into the Collaboration Agreement giving Janssen Biotech the option to collaborate with Idorsia to jointly develop and solely commercialize aprocitentan (ACT-132577) and any of its derivative compounds or products. Aprocitentan is being investigated for use in resistant hypertension and has completed a dose-finding study in essential hypertension. Following the latter of the end of the Phase 2 study meeting with the FDA or receipt by Janssen Biotech of a complete Phase 2 data package, Janssen Biotech will have thirty days to opt in to the collaboration by paying Idorsia a milestone payment of USD 230 million. In addition, under the terms of the Collaboration Agreement, Janssen Biotech will pay Idorsia royalties on products containing aprocitentan.

Revenue Sharing Agreement with Johnson & Johnson

Idorsia Pharmaceuticals Ltd, J&J and Actelion Pharmaceuticals Ltd have entered into the Revenue Sharing Agreement in respect of ponesimod and cadazolid. Under the terms of the Revenue Sharing Agreement, Idorsia Pharmaceuticals Ltd is entitled to receive quarterly payments of 8% of the aggregate net sales of ponesimod and cadazolid products from Actelion Pharmaceuticals Ltd.

Collaboration Agreement with ReveraGen

In April 2016, Actelion Pharmaceuticals Ltd signed a collaborative agreement with ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of Duchenne Muscular Dystrophy (“DMD”). This collaborative agreement, including all rights and obligations, was transferred to Idorsia Pharmaceuticals Ltd. Consequently, Idorsia will be entitled to exercise an option to obtain the exclusive worldwide license rights on vamorolone at any time, but not later than upon receipt of the Phase 2b study results for a consideration of USD 45 million. If the option is exercised, ReveraGen will be entitled to receive milestone payments up to USD 120 million for the approval and commercialization in the DMD indication, and up to USD 190 million in three additional indications. Furthermore, Idorsia will pay increasing tiered double-digit royalties on the net sales of vamorolone and will support R&D activities up to a maximum amount of USD 1 million per annum for the next twenty-two months unless earlier terminated or extended.

Equity stake in Vaxxilon AG

In 2015, Actelion established Vaxxilon as a new majority owned company which aims to discover, develop, and commercialize synthetic carbohydrate vaccines. Vaxxilon was incorporated under the laws of Switzerland together with the Max Planck Society, a publicly funded non-profit organization in Munich, Germany, and Seeberger Science GmbH, a private company in Kleinmachnow, Germany. Actelion was the principal investor and majority shareholder, holding a 73.9% equity stake of the company. Vaxxilon has licensed exclusive rights to multiple preclinical vaccine candidates and additional technologies from MPI.

The equity stake of 73.9% as well as all rights and obligations in connection with Vaxxilon were transferred to Idorsia. Consequently, Idorsia is committed to provide funding of up to the CHF equivalent of EUR 9.4 million to Vaxxilon, contingent upon successful completion of predefined clinical and development milestones and will be released over an estimated period of two to three years.